Additional Relevant Details Shire and its partner Shionogi & Co announced that it has filed a New Drug Application in Japan for S-877503 (guanfacine hydrochloride prolonged release tablets).  The drug is to be used to treat ADHD in children 6-17 years old.  The average reviewal process for a NDA in Japan is around 12 months.  Shionogi is a Japan-based pharmaceutical company focused on the research and development of treatments for various therapeutic areas.